Fig. 2From: Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancerOverall survival according to ESR1 mutation status at progression disease. p value was determined using a log-rank testBack to article page